...
首页> 外文期刊>Current opinion in drug discovery & development >Anti-inflammatory drug development: Broad or specific chemokine receptor antagonists?
【24h】

Anti-inflammatory drug development: Broad or specific chemokine receptor antagonists?

机译:抗炎药开发:广泛的或特定的趋化因子受体拮抗剂?

获取原文
获取原文并翻译 | 示例
           

摘要

Chemokines and chemokine receptors form a complex and diverse system known to be relevant for leukocyte activation and trafficking. There has been significant interest in the development of anti-inflammatory drugs that antagonize the function of chemokines or their receptors. However, the translation of results from animal models to human disease has not been simple, and drug development in the field has failed in many instances, leading to the question of whether targeting several chemokines may be more useful than targeting a single chemokine or receptor. This question has no simple answer. The complexity of the chemokine system may result in functional redundancy, which is not absolute. However, this complexity is likely important for the physiology of the immune system. The success of future development of therapies targeting chemokines and their receptors requires a complete understanding of the diversity and complexity of the system in human chronic inflammatory diseases and infection.
机译:趋化因子和趋化因子受体形成了一个复杂多样的系统,已知与白细胞激活和运输有关。对抗趋化因子或其受体功能的抗炎药的开发引起了极大的兴趣。然而,从动物模型到人类疾病的结果转化并不简单,并且在许多情况下该领域的药物开发都失败了,这带来了一个问题,即靶向几种趋化因子是否比靶向单一趋化因子或受体更有用。这个问题没有简单的答案。趋化因子系统的复杂性可能导致功能冗余,这不是绝对的。但是,这种复杂性对于免疫系统的生理可能很重要。靶向趋化因子及其受体的疗法的未来发展的成功需要对人类慢性炎性疾病和感染中系统的多样性和复杂性有一个完整的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号